Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.

@article{Eshleman2004ComparisonON,
  title={Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.},
  author={Susan H Eshleman and Laura A. Guay and Anthony Mwatha and Shawn Cunningham and Elizabeth R. Brown and Philippa Musoke and Francis A Mmiro and Jay Brooks Jackson},
  journal={AIDS research and human retroviruses},
  year={2004},
  volume={20 6},
  pages={
          595-9
        }
}
We compared nevirapine (NVP) resistance (NVPR) mutations in maternal plasma 7 days vs. 6-8 weeks after single-dose NVP prophylaxis. In the HIVNET 012 trial, Ugandan women received a single dose of NVP in labor for prevention of HIV-1 mother-to-child transmission. NVPR mutations were detected in 70 (25%) of 279 women 6-8 weeks after NVP. Samples collected 7 days after NVP were analyzed from a subset of those 279 women. Genotyping was performed with the ViroSeq HIV-1 Genotyping System. NVPR was… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 28 CITATIONS

Linked dual-class HIV resistance mutations are associated with treatment failure.

Valerie F Boltz, Wei Shao, +12 authors John W Mellors
  • JCI insight
  • 2019
VIEW 2 EXCERPTS
CITES BACKGROUND